Fluorescent α-conotoxin [d-Lys11]LvIC-BDP maps α6β4 nAChRs, showing reduced expression in rat IC/BPS.

The α6β4 nicotinic acetylcholine receptors (nAChRs) are emerging as promising therapeutic targets for pain management, yet their study has been significantly hampered by a scarcity of selective pharmacological tools. Current methods lack the specificity and stability required for detailed in vivo distribution and functional characterization. This gap limits our understanding of their role in conditions like Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), a chronic pain condition of the bladder, and impedes the development of targeted therapies that could modulate nAChR activity for pain relief.

Researchers developed a stable, selective α-conotoxin analogue, [d-Lys11]LvIC, derived from [D1G, Δ14Q]LvIC. They evaluated its half-maximal inhibitory concentration (IC50), selectivity against 11 other nAChR subtypes, and stability in rat serum. Based on its favorable properties, they conjugated [d-Lys11]LvIC to a BODIPY-FL (BDP) fluorophore to create [d-Lys11]LvIC-BDP, a high-fidelity fluorescent probe. This probe was then preliminarily applied to investigate α6β4 nAChRs tissue distribution in the rat urinary tract and to detect changes in expression within a cyclophosphamide (CYP)-induced rat model of IC/BPS.

The rationally designed mutant, [d-Lys11]LvIC, demonstrated potent and selective inhibition of heterologous rat α6/α3β4 nAChRs with an IC50 of 8.2 nM. Crucially, this analogue maintained substantial selectivity for 11 other nAChR subtypes and exhibited superior stability in rat serum compared to its precursor. The subsequent [d-Lys11]LvIC-BDP fluorescent probe successfully enabled the investigation of α6β4 nAChRs tissue distribution in rats. This probe's utility was highlighted in a preliminary application: > The [d-Lys11]LvIC-BDP probe detected a reduction in α6β4 nAChRs expression within the urinary tract of a cyclophosphamide (CYP)-induced rat model of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).